Effect of phosphodiesterase inhibitors in the bladder

Asian Journal of Urology, 2015, 2 (1): 33-37 doi:

Review

Current Issue | Archive | Adv Search

Effect of phosphodiesterase inhibitors in the bladder

Bilal Chughtai, Aizaz Ali, Claire Dunphy, Steven A. Kaplan

Weill Cornell Medical College, New York City, NY, USA

Abstract
Related Citation (0)

Download:

HTML

PDF (329KB)
Export: BibTeX | EndNote (RIS)

Abstract Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients. PDE5 inhibitors mediate their effects through several pathways including cAMP, NO/cGMP, Kchannel modulated pathways, and the L-cysteine/H₂S pathway. PDE5 inhibitors exert their effect in muscle cells, nerve fibers, and interstitial cells (ICs). The use of PDE5 inhibitors led to improvement in LUTS. This included urodynamic parameters. PDE5 inhibitors may play a significant role in LUTS due to their effect on the bladder rather than the prostate.

Key words： Lower urinary tract symptoms (LUTS) Overactive bladder syndrome (OAB) Phosphodiesterase type 5 inhibitors NO/cGMP cAMP

Published: 06 February 2015

Corresponding Authors: Bilal Chughtai E-mail: Bic9008@med.cornell.edu

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Bilal Chughtai
	Aizaz Ali
	Claire Dunphy
	Steven A. Kaplan

TRENDMD:

Cite this article:

Bilal Chughtai,Aizaz Ali,Claire Dunphy, et al. Effect of phosphodiesterase inhibitors in the bladder[J]. Asian Journal of Urology, 2015, 2(1): 33-37.

URL:

http://www.ajurology.com/EN/ OR http://www.ajurology.com/EN/Y2015/V2/I1/33

[1]	Girman CJ. Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology 1998;51(4A Suppl.):8-12.
[2]	McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185: 1793-803.
[3]	Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8.
[4]	Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50: 1306-15.
[5]	Herschorn S, Gajewski J, Schulz J, Corcos J. A populationbased study of urinary symptoms and incontinence: the Canadian urinary bladder survey. BJU Int 2008;101:52-8.
[6]	Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, et al. Characterization and functional role of androgendependent PDE5 activity in the bladder. Endocrinology 2007; 148:1019-29.
[7]	Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010;7(1 Pt 1):59-69.
[8]	Truss MC, Uckert S, Stief CG, Kuczyk M, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res 1996;24:123-8.
[9]	Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93:280-91.
[10]	Oger S, Behr-Roussel D, Gorny D, Lebret T, Validire P, Cathelineau X, et al. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 2010;160:1135-43.
[11]	Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ. Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 2012; 110(6 Pt B):E259-66.
[12]	Xin W, Cheng Q, Soder R, Rovner E, Petkov GV. Constitutively active phosphodiesterase activity regulates urinary bladder smooth muscle function: critical role of KCa1.1 channel. Am J Physiol Renal Physiol 2012;303:F1300-6.
[13]	Fusco F, di Villa Bianca Rd, Mitidieri E, Cirino G, Sorrentino R, Mirone V. Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol 2012; 62:1174-80.
[14]	Artim DE, Kullman FA, Daugherty SL, Wu HY, de Groat WC. Activation of the nitric oxideecGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G. Am J Physiol Renal Physiol 2009;297:F333-40.
[15]	Yanai Y, Hashitani H, Hayase M, Sasaki S, Suzuki H, Kohri K. Role of nitric oxide/cyclic GMP pathway in regulating spontaneous excitations in detrusor smooth muscle of the guineapig bladder. Neurourol Urodyn 2008;27:446-53.
[16]	Fujiwara M, Anderson K, Persson K. Nitric oxide-induced cGMP accumulation in the mouse bladder is not related to smooth muscle relaxation. Eur J Pharmacol 2000;401:241-50.
[17]	Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide phosphodiesterases in rabbit retrusor smooth muscle. Urology 2002;59:145-9.
[18]	Werkstrom V, Hedlund P, Lee T, Anderson KE. Vardenafilinduced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int 2009;104: 1740-5.
[19]	Rahnama'i M, Van Koeveringe GA, Van Kerrebroeck PE. Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction. Nephrourol Mon 2013;5:934-45.
[20]	Gillespie JI, Markerink-van Ittersum M, de Vente J. cGMPgenerating cells in the bladder wall: identification of distinct networks of interstitial cells. BJU Int 2004;94:1114-24.
[21]	Gillespie JI, Markerink-van Ittersum M, de Vente J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005;321:341-51.
[22]	Gillespie JI, Markerink-van Ittersum M, De Vente J. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res 2006;325:325-32.
[23]	Behr-Roussel D, Oger S, Caisey S, Sandner P, Bernabe J, Alexandre L, et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cordinjured rats. Eur Urol 2011;59:272-9.
[24]	Artim DE, Kullmann FA, Daugherty SL, Bupp E, Edwards CL, de Groat WC. Developmental and spinal cord injury-induced changes in nitric oxide-mediated inhibition in rat urinary bladder. Neurourol Urodyn 2011;30:1666-74.
[25]	Mirzaii-Dizgah I, Salmanyan B. Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors. Eur Spine J 2013;22:2766-9.
[26]	Morelli A, Filippi S, Comeglio P, Sarchielli E, Chavalmane AK, Vignozi L, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7(1 Pt 1):107-20.
[27]	Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Keys T, et al. Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol 2013;189:754-61.
[28]	Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002;90:836-9.
[29]	Mulhall J, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-7.
[30]	McVary KT, Monnig W, Camps Jr JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177:1071-7.
[31]	Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-34.
[32]	Gacci M, Lerardi A, Rose A, Tazzioli S, Scapatici E, Filippi S, et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med 2010;7(1 Pt 1):234-43.
[33]	Gacci M, Del Popolo G, Macchiarella A, Celso M, Vittori G, Lapini A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007;178:2040-3.
[34]	Taie K, Moombeini H, Khazaeli D, Salari Panah Firouzabadi M. Improvement of urodynamic indices by single dose oral tadalafil in men with supra sacral spinal cord injury. Urol J 2010;7: 249-53.